Special Issue "Emerging Concepts in SARS-CoV-2 Biology and Pathology"
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 12287
Interests: virology; emerging viruses; pandemics; viral evolution; hematology; immunogenetics; transplant immunology; transfusion medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue in Viruses: SARS-CoV-2 inside and outside the Respiratory Tract: From Diagnostics to Therapies
Special Issue in International Journal of Molecular Sciences: SARS-CoV-2 Variants, Antibodies and Vaccines
Special Issue in Life: COVID-19 Convalescent Plasma for Immuno-Compromised Patients
Special Issue in Life: Epidemiology of Viral Zoonosis
Special Issue in Viruses: Emerging Concepts in SARS-CoV-2 Biology and Pathology 2.0
Special Issue in International Journal of Molecular Sciences: Influenza Viruses: Infection and Genomics
Much has been learnt about SARS-Co-2 biology, but much also remains to be learned. Despite currently driving pathology mostly in immunocompromised patients, SARS-CoV-2 is still evolving at rates much higher than for other human RNA viruses, with convergence over moving Spike targets, but globally increasing its genetic and serological distance. The source of the pandemic has been redefined as a panzootic disease of placental mammals, leaving room for reverse zoonoses. The virus has also been shown to be able to compartmentalize and persist, even in immunocompetent hosts, where it can cause long-lasting symptoms for which directly acting antivirals are under investigation. Unfortunately, many emergency-use authorized drugs are providing marginal benefits in vaccinated patients, and none of the anti-Spike monoclonal antibodies authorized so far are effective against emerging Omicron variants. Fundamental virology has discovered how SARS-CoV-2 carries miRNA-like molecules able to suppress the immune response and how the genome can integrate. In this Special Issue, we will collect advances in epidemiology and fundamental virology, as well as novel therapeutics.
Dr. Daniele Focosi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.